Anaptys Biosciences Inc.

According to the CEO of Anaptys Biosciences, therapeutic antibodies will continue to be the single largest growing segment in pharmaceuticals, but the number of companies providing solutions in this area is decreasing following a number of acquisitions. Anaptys will fill the gap with its somatic hypermutation technology platform for therapeutic antibody discovery and optimization. The platform replicates the natural process of mutagenesis occurring in B cells as part of the immune response, involving steps of immunoglobulin recombination, mutation, affinity maturation and selection.